Capitalizing on lean staffing and working to develop a new generation of top litigators, Cooley has set itself apart with a recent trio of high-stakes trial victories. And it has done so by relying on a broad array of lawyers with both trial and scientific expertise. “If you look at our cases, it’s not one lawyer that’s the common denominator,” says partner Michael Rhodes. It’s a formula that appears to be working: Although less than 10 percent of the firm’s lawyers practice in the department, IP litigation accounts for roughly 19 percent of Cooley’s revenue.
Significant Cases: Representing Gilead Sciences Inc. in a heated arbitration battle with Hoffman-La Roche Inc., a Cooley team led by firm chairman Stephen Neal protected the patent rights on Sovaldi, a hepatitis C therapy that Gilead had spent $11 billion to acquire in 2012. In August 2014, an arbitration panel sided with Cooley’s client, finding that Roche had failed to establish a patent or contact claim that entitled it to rights over the drug.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
